Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Neurocrine Biosciences (NBIX) stocks in Canada
Learn how to easily invest in Neurocrine Biosciences stocks.
Neurocrine Biosciences is a drug manufacturers-specialty & generic business based in the US. Neurocrine Biosciences stocks (NBIX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $98.99 – an increase of 3.72% over the previous week. Neurocrine Biosciences employs 917 staff and has a trailing 12-month revenue of around $1.1 billion.
How to buy shares in Neurocrine Biosciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NBIX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Neurocrine Biosciences?
- Has coronavirus impacted Neurocrine Biosciences shares?
- Neurocrine Biosciences shares summary
- Compare share dealing platforms
- Is Neurocrine Biosciences stock a buy or sell?
- Neurocrine Biosciences performance over time
- Are Neurocrine Biosciences shares over-valued?
- Neurocrine Biosciences's financials
- How volatile are Neurocrine Biosciences shares?
- Does Neurocrine Biosciences pay a dividend?
- Other common questions
Neurocrine Biosciences stock price (NASDAQ:NBIX)Use our graph to track the performance of NBIX stocks over time.
Neurocrine Biosciences shares at a glance
|Latest market close||$75.51|
|52-week range||$71.88 - $120.01|
|50-day moving average||$83.11|
|200-day moving average||$92.96|
|Wall St. target price||$119.32|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$4.54|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Neurocrine Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Neurocrine Biosciences price performance over time
|1 week (2022-01-17)||N/A|
|1 month (2021-12-27)||-10.63%|
|3 months (2021-10-28)||-25.88%|
|6 months (2021-07-28)||-19.60%|
|1 year (2021-01-28)||-32.54%|
|2 years (2020-01-28)||-25.67%|
|3 years (2019-01-28)||88.86|
|5 years (2017-01-27)||87.09%|
Is Neurocrine Biosciences under- or over-valued?
Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neurocrine Biosciences's P/E ratio
Neurocrine Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Neurocrine Biosciences shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Neurocrine Biosciences's PEG ratio
Neurocrine Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.87. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Neurocrine Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Neurocrine Biosciences's EBITDA
Neurocrine Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $225.7 million.
The EBITDA is a measure of a Neurocrine Biosciences's overall financial performance and is widely used to measure a its profitability.
Neurocrine Biosciences financials
|Revenue TTM||$1.1 billion|
|Operating margin TTM||20.16%|
|Gross profit TTM||$760.8 million|
|Return on assets TTM||7.66%|
|Return on equity TTM||41.37%|
|Market capitalisation||$7.1 billion|
TTM: trailing 12 months
Neurocrine Biosciences share dividends
We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.
Neurocrine Biosciences share price volatility
Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $71.88 up to $120.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.7329. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).
Neurocrine Biosciences overview
Neurocrine Biosciences, Inc. , a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression.
Stocks similar to Neurocrine Biosciences
Neurocrine Biosciences in the news
Neurocrine price target lowered to $114 from $123 at Piper Sandler
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results
Declining Stock and Solid Fundamentals: Is The Market Wrong About Neurocrine Biosciences, Inc. (NASDAQ:NBIX)?
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
How to buy Haemonetics Corporation stock in Canada
Steps to owning and managing HAE stock, with 24-hour and historical pricing before you buy.
How to buy Aritzia stock in Canada
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
CI Direct Trading review
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Hifi Finance (MFT) price prediction
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.
How to buy The Sandbox (SAND) in Canada
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
Shiba Inu (SHIB) price, history and performance
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
Baby Doge Coin (BABYDOGE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
Pendle (PENDLE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Pendle, lists some exchanges where you can get it and provides daily price data on PENDLE.
Hempcoin (THC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Hempcoin, lists some exchanges where you can get it and provides daily price data on THC.
Ask an Expert
You must be logged in to post a comment.